NOV 22, 2015 9:15 AM PST

Kill Cancer with an Intelligent, Injectable Gel?

WRITTEN BY: Xuan Pham
A new way of treating cancer may come in the form of an injectable gel. The “biogel” was developed in lab of Réjean Lapointe at the University of Montreal Hospital Research Centre, to provide a better way to deliver anti-cancer immune cells to patients.
 
Researchers examine the injectable cancer-killing gel

“The strength of this biogel is that it is compatible with anti-cancer immune cells. It is used to encapsulate these cells and eventually administer them using a syringe or catheter into the tumour or directly beside it. Instead of injecting these cells or anti-cancer drugs throughout the entire body via the bloodstream, we can treat the cancer locally. We hope that this targeted approach will improve current immunotherapies.” Réjean Lapointe, senior author of the study.
 
Current immunotherapy techniques that use the patient’s own T cells to fight off cancer has been well established. But because the body’s natural T cells are insufficient in number and strength to fight off cancer fully, scientists devised a method give the T cells more firepower. Known as adoptive cell therapy (ACT), scientists collect the patient’s own T cells, modify them to enhance tumor recognition, increase their numbers to billions, and then inject them back into the patient to finish the job.
 
While this technique has shown to be effective in small trials involving leukemia and lymphoma patients, there are several limitations: extraordinarily high cell count requirement, and toxicity due to high doses of interleukin-2, a hormone added to maximize effectiveness.
 
The biogel breaks through these limitations as it requires millions of T cells instead of billions, and in the process, significantly reduces the toxicity by the interleukin-2 hormone. Developed by Sophie Lerouge, the biogel is made from biodegradable material taken from the shells of crustaceans. The biogel is liquid at room temperature and becomes a cohesive gel at 37 degrees Celsius, the human body temperature. Additionally, the biogel is non-toxic to the body and “provided excellent survival and growth of the encapsulated cells,” said Lerouge. Once inside the body, the gel serves as a “cellular reservoir” deploying and renewing the cancer-killing T cells.
 
"The T lymphocytes in the gel are functional and can grow for two to three weeks, be released from the gel, and kill the cancerous cells," explained Réjean Lapointe, senior author.
 
Early in vitro experiments testing the gel on melanoma and kidney cancer models have so far been reported as successful. The researchers plan to test the biogel in animal models, and if effective, will move towards human trials. If the biogel performs well, the tool will likely be adapted to treat many types of cancer in the next few years.
 
 
Sources: BioMaterials, Science Daily
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 17, 2020
Microbiology
Ingestible Bacteria-Catcher Could Act as a Diagnostic Tool
AUG 17, 2020
Ingestible Bacteria-Catcher Could Act as a Diagnostic Tool
Microbes in our gastrointestinal tract may not only be closely linked to our health, but they may also be useful as a di ...
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 27, 2020
Clinical & Molecular DX
A Super Sensitive Alzheimer's Test Powered by Nanozymes
OCT 27, 2020
A Super Sensitive Alzheimer's Test Powered by Nanozymes
  Simple tasks are now uphill struggles, social situations aren’t fun, and the car keys are missing again. By ...
OCT 29, 2020
Clinical & Molecular DX
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
OCT 29, 2020
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
 
OCT 24, 2020
Clinical & Molecular DX
Software Flags Elevated Cerebral Palsy Risk in Premies
OCT 24, 2020
Software Flags Elevated Cerebral Palsy Risk in Premies
Diagnostic imaging scientists have developed a software tool for predicting the future onset of cerebral palsy in babies ...
NOV 17, 2020
Clinical & Molecular DX
Tumor Stiffness Linked to Its Aggressiveness
NOV 17, 2020
Tumor Stiffness Linked to Its Aggressiveness
  As tumors grow, tiny areas at their cores are found to become stiff prior to metastasis, or the spread of cancer ...
Loading Comments...